[1]蔡智源,何朝滨,陈 尚,等.肝内胆管癌TACE治疗患者的预后因素分析[J].介入放射学杂志,2021,30(03):291-295.
 CAI Zhiyuan,HE Chaobin,CHEN Shang,et al.Analysis of prognostic factors in patients with intrahepatic cholangiocarcinoma after receiving transcatheter arterial chemoembolization[J].journal interventional radiology,2021,30(03):291-295.
点击复制

肝内胆管癌TACE治疗患者的预后因素分析()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年03
页码:
291-295
栏目:
临床研究
出版日期:
2021-03-29

文章信息/Info

Title:
Analysis of prognostic factors in patients with intrahepatic cholangiocarcinoma after receiving transcatheter arterial chemoembolization
作者:
蔡智源 何朝滨 陈 尚 周京晶 梁颖凤 陈 晓 林小军
Author(s):
CAI Zhiyuan HE Chaobin CHEN Shang ZHOU Jingjing LIANG Yingfeng CHEN Xiao LIN Xiaojun.
Department of Pancreatobiliary Surgery, State Key Laboratory of Oncology in South China, SUN Yat-sen University Cancer Center, Guangzhou, Guangdong Province 510060, China
关键词:
【关键词】 肝内胆管癌 肝动脉栓塞化疗 中性粒细胞/淋巴细胞比值 预后
文献标志码:
A
摘要:
【摘要】 目的 分析肝内胆管癌TACE后患者的预后因素。方法 回顾性分析144例接受TACE治疗的原发性肝内胆管癌患者的临床资料,分析其术前各项指标与生存预后的关系。结果 以外周血中性粒细胞淋巴细胞比值(NLR)=2.8作为最佳截断值,低NLR组患者的中位总生存时间(mOS)为27.0个月,高NLR组患者的mOS为10.8个月,低NLR组患者mOS明显长于高NLR组(1年生存率75.0%比 43.5%,2年生存率51.1%比22.0%,P=0.004)。低NLR组患者的中位无进展生存时间(mPFS)为4.7个月,高NLR组患者的mPFS为2.5个月,两组患者之间的mPFS差异有统计学意义(P<0.05)。单因素分析显示区域淋巴结转移、肝外转移、ALP、GGT、AFP、CA19-9、NLR和血小板淋巴细胞比值(PLR)均是影响总体生存时间的预后因素,而NLR、CA19-9和血管侵犯是影响mPFS的预后因素。多因素分析提示,术前NLR是影响总体生存的独立预后因素。结论 术前外周血NLR水平是影响肝内胆管癌患者行TACE治疗的独立预后因素,高NLR提示肝内胆管癌患者TACE的治疗效果较差。

参考文献/References:

[1] Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2015, 111: 213-220.
[2] Lieser MJ, Barry MK, Rowland C, et al. Surgical management of intrahepatic cholangiocarcinoma: a 31- year experience[J]. J Hepatobiliary Pancreat Surg,1998, 5: 41- 47.
[3] Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2015, 111: 213-220.
[4] Balkwill F, Mantovani A. Inflammation and cancer: back to virchow?[J]. Lancet, 2001, 357: 539-545.
[5] 严守美,崔新江,于志军,等. 经肝动脉化疗栓塞联合微波消融治疗巨块型肝癌术前中性粒细胞与淋巴细胞比率监测的临床意义[J]. 介入放射学杂志, 2018, 27: 632-635.
[6] 张凤春,江 莺,刘照南,等. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33: 34-39.
[7] 陈 涛,许海生,杨晓虹. 中性粒细胞/淋巴细胞比值及GPS评分与肺癌预后的关系[J]. 临床研究, 2019, 27: 139-141.
[8] Chen Q, Yang LX, Li XD, et al. The elevated preoperative neutrophil- to- lymphocyte ratio predicts poor prognosis in intrahe patic cholangiocarcinoma patients undergoing hepatectomy[J]. Tumor Biol, 2015, 36: 5283-5289.
[9] 何朝滨,林小军. 中性粒细胞/淋巴细胞比值血小板/淋巴细胞比值与TACE治疗肝癌患者预后的相关性[J]. 中国肿瘤临床, 2017, 44: 283-288.
[10] Colotta F, Allavena P, Sica A, et al. Cancer- related inflammation, the seventh hallmark of cancer: links to genetic instability[J]. Carcinogenesis, 2009, 30: 1073-1081.
[11] Dupre A, Malik HZ. Inflammation and cancer: what a surgical oncologist should know[J]. Eur J Surg Oncol, 2018, 44: 566-570.
[12] Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362: 1273-1281.
[13] 郝文胜,张东成,桂 东,等. 替吉奥联合奥沙利铂一线治疗晚期肝内胆管癌患者疗效和安全性评价[J]. 实用肝脏病杂志. 2015, 18: 415- 417.
[14] 王卫东,倪嘉延,许林锋. 对比微球与传统碘油栓塞治疗原发性肝癌疗效[J]. 中华介入放射学电子杂志, 2014, 2: 56- 60.
[15] Gkika E, Hallauer L, Kirste S, et al. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma[J]. BMC Cancer, 2017, 17:781.
[16] 生守鹏,郑加生,崔石昌,等. 肝动脉化疗栓塞联合CT引导热消融治疗肝内胆管癌[J]. 介入放射学杂志, 2017, 26: 618- 621.
[17] 张荷月,金添强,戴朝六,等. 肝内胆管细胞癌免疫治疗和靶向治疗研究现状[J]. 中国肿瘤临床, 2019, 46: 694- 699.

相似文献/References:

[1]徐增斌,彭志毅,章熙道,等.小肝癌DSA诊断作介入治疗[J].介入放射学杂志,1996,(01):45.
[2]罗中华,秦 勉,张学昕,等.原发性肝癌合并下腔静脉及右心房癌栓的动脉内化疗栓塞治疗[J].介入放射学杂志,2012,(12):1035.
 LUO Zhong? hua,QIN Mian,ZHANG Xue? xin,et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by tumor thrombus in inferior vena cava and right atrium[J].journal interventional radiology,2012,(03):1035.
[3]李毅斌,曹漫明,胡喜钢,等.射频消融术联合肝动脉化疗栓塞及西妥昔单抗治疗结直肠癌肝转移的疗效评价[J].介入放射学杂志,2016,(02):129.
 LI Yi- bin,CAO Man- ming,HU Xi- gang,et al. Evaluation of radiofrequency ablation combined with transcatheter arterial chemoembolization and cetuximab in treating hepatic metastases from colorectal cancer[J].journal interventional radiology,2016,(03):129.
[4]王晓维,付守忠,戴 锋,等.肝动脉栓塞化疗联合射频消融与联合微波消融治疗原发性肝癌的疗效和安全性比较 [J].介入放射学杂志,2016,(08):673.
 WANG Xiao-wei,FU Shou-zhong,DAI Feng,et al.The curative effect and safety in treating primary hepatocellular carcinoma: comparison between TACE plus radiofrequency ablation and TACE plus microwave ablation [J].journal interventional radiology,2016,(03):673.
[5]刘光华,俞炬明,范国平,等.肝细胞癌患者伴发糖尿病行肝动脉化疗栓塞术的预后因素分析 [J].介入放射学杂志,2017,(10):926.
 LIU Guanghua,YU Juming,FAN Guoping,et al.Analysis of prognostic factors in patients with hepatocellular carcinoma complicated by diabetes mellitus after transcatheter arterial chemoembolization[J].journal interventional radiology,2017,(03):926.

备注/Memo

备注/Memo:
(收稿日期:2020-01-10)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2021-03-25